MADISON, Wisconsin. January 12, 2010 – Centrose LLC, a biotechnology company focused on making better drugs has elected Dr. Troy Wilson to the Executive Board of Members. Dr. Wilson is a serial biotechnology entrepreneur and brings significant experience in founding and leading biotechnology companies. He currently serves as President and Chief Executive Officer of Intellikine, a company focused on developing drugs against the PI3K/mTOR pathway. He is also a co-founder of Ambrx and Phenomix. Dr. Wilson previously served as Vice President, Business Development and General Counsel at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego. He received his Ph.D. in bioorganic chemistry from the University of California, Berkeley and his law degree from New York University.
”As we strengthen our focus on anti-cancer therapeutic discovery and begin the process of taking our leads to the next stage of development, Troy brings a significant new dimension to the leadership of Centrose,” said Dr. James Prudent, President and Chief Executive Officer of Centrose.
About Centrose LLC
Centrose delivers powerful technologies for the enhancement of therapeutics and is using these technologies to enhance anti-cancer and anti-infective drugs. Specifically, Centrose is attaching novel sugars and targeting molecules to enhance the pharmaceutical properties of drugs with established therapeutic potential. The Company uses the proprietary CarboConnect® system to enhance, screen and fine tune drug action. Centrose obtains exclusive rights to technologies that allow it’s scientists to enhance drugs and continues to develop and patent new enhancing technologies and drug leads.
James Prudent, Ph.D.
Chief Executive Officer